Tag: Bristol
Merck scraps Keytruda lung cancer trial adding Bristol Myers’ Yervoy. What...
Merck’s Keytruda is without doubt the king in previously untreated non-small cell lung cancer, but the company wanted to see whether adding another immuno-oncology agent...
Bristol Myers’ Opdivo clears signs of lung cancer in first-in-class pre-surgery...
Bristol Myers Squibb’s Opdivo may not be the most popular immunotherapy for treating metastatic non-small cell lung cancer, but it’s now the first to report...
Bristol Myers Squibb’s targeted AML drug Idhifa fails to extend patients’...
Back in 2017, the FDA cleared Celgene's acute myeloid leukemia therapy Idhifa based on complete remission data. But fast forward to today, and the drug has...
Former Bristol Myers Squibb site marketed as the new home for...
As pandemic lockdowns begin to ease, the U.S. government has shown some interest––and deep pockets––in bringing drugmakers' supply chains stateside to bolster supplies during...
Bristol Myers Squibb’s Zeposia angles for lucrative ulcerative colitis nod with...
Bristol Myers Squibb notched a big win with its recent approval of multiple sclerosis drug Zeposia, a Celgene pipeline pickup with blockbuster aspirations. Not content to ride its...
Bristol Myers Squibb’s Zeposia launches into crowded MS market
When Bristol Myers Squibb nabbed Celgene's long-sought FDA nod for multiple sclerosis drug Zeposia, the COVID-19 pandemic was in full swing—not the ideal time...
Bristol Myers, Acceleron’s Reblozyl moves closer to blockbusterland with new blood...
As a potential blockbuster drug touted by Bristol Myers Squibb during its Celgene buyout, Reblozyl’s future success was in large part dependent on an...
